Why does phenylephrine decrease frontal lobe oxygenation but increase cerebral blood flow velocity?
Hypotension represents the most frequent side effect of anesthesia. Its correction is of importance to secure perfusion pressure of vital organs such as the brain. As discussed in a previous post, I have been interested in the impact of vasopressors on cerebral blood flow and oxygenation since my postdoc. We, and others, have reported that the utilization of vasopressors increasing mean arterial pressure by peripheral vasoconstriction was associated with a reduction in frontal lobe oxygenation. We observed such results in the laboratory in normotensive healthy subjects and in the operating room in hypotension patients undergoing elective surgery.
We need to better understand what explains a reduction in frontal lobe oxygenation following the utilization of vasopressors like phenylephrine or norepinephrine because 1) these agents are first-line agents used to correct mean arterial pressure in hypotensive states and 2) a reduction in cerebral oxygenation during surgeries such as a coronary artery bypass is associated with neurological impairments after the surgery and neurological outcomes seem to be improved when the reduction in cerebral oxygenation is prevented or corrected.
One intriguing observation reported by Ainslie’s group as well as our research group was that bolus/infusion of phenylephrine, a selective alpha-adrenergic agent, was associated with a reduction in frontal lobe oxygenation, but also with an increase in cerebral blood flow velocity measured in the middle cerebral artery. This was intriguing because one could argue that a reduction in cerebral oxygenation is the consequence of a reduction in flow. One suggestion could be that phenylephrine induces (whether directly or indirectly via a reduction in cardiac output) vasoconstriction of the middle cerebral artery, leading to an increase in cerebral blood flow velocity (remember that we are not measuring blood flow but blood flow velocity with transcranial doppler) and a decrease in frontal lobe oxygenation.
Shigehiko Ogoh’s research team investigated that issue by evaluating the influence of phenylephrine on frontal lobe oxygenation (by near-infrared spectroscopy) and middle cerebral artery flow velocity (transcranial doppler) and blood flow changes in the internal carotid artery and internal jugular vein (by duplex ultrasonography).
The main results are presented in the figure below:
As others did, this team observed reduced frontal lobe oxygenation (not in the figure) and increased middle cerebral artery blood flow (MCAVmean) with infusion of phenylephrine vs. saline. Interestingly, blood flow in the internal carotid artery (ICA BF) did not change and blood flow in the internal jugular vein (IJV BF) increased (due to an enlargement of internal carotid artery diameter). No change in arterial oxygen or carbon dioxide tensions was observed. However, phenylephrine did not decrease cardiac output.
What was the interpretation of the authors?
The results suggest that the decrease in frontal lobe oxygenation during phenylephrine infusion is caused by a smaller arterial and larger venous contribution to the NIRS signal as an elevated MCAVmean with constant ICA flow conforms to elevated arterial tone, while venous tone is reduced as indicated by an enlarged IJV diameter
So phenylephrine seems to constrict the middle cerebral artery while cerebral blood flow is maintained. Although further research is needed to support such findings and explain how this agent could directly constrict this artery without crossing an intact blood brain barrier, this study suggests that the utilization of phenylephrine don’t interrupt delivery of oxygen to the brain despite the reduction observed in frontal lobe oxygenation.
The authors suggest that the reduction in frontal lobe oxygenation could be related to a shift in the arterial versus venous contribution to the near-infrared signal (used to measure frontal lobe oxygenation). Indeed, an increased blood flow from the vertebral arteries (with no change in internal carotid artery blood flow) could have contributed to the higher venous blood flow during the infusion of phenylephrine. In addition, the authors suggested that we cannot exclude the influence of skin blood flow on the near-infrared signal.
These results and interpretations are very interesting and definitely move the field forward. However, one needs to keep in mind that a reduction in cerebral oxygenation has been associated with neurological impairments following cardiac surgeries. I am not convinced that this could be explained by a redistribution of cerebral blood flow or a reduction in skin blood flow.
One final issue I would like to discuss is the absence of impact of phenylephrine on cardiac output. We and others have reported reduced cardiac output with the administration of phenylephrine. As discussed in other posts (here and here), the potential mechanisms underlying the modulation of cerebral oxygenation by cardiac output could be sympathetically mediated vasoconstriction induced by a lowering in cardiac output or it could also depend on the distribution of circulating blood volume. So, the results from Ogoh’s group cannot be necessarily generalized to subjects experiencing a reduction in cardiac output with phenylephrine.
Further research is warranted to characterize the influence of vasopressors on cerebral perfusion/oxygenation and as Ogoh’s team did, we need to measure blood flow/blood flow velocity in different arteries during infusion studies in order to have a more complete picture.
Ogoh, S., Sato, K., Fisher, J. P., Seifert, T., Overgaard, M., & Secher, N. H. (2011). The effect of phenylephrine on arterial and venous cerebral blood flow in healthy subjects. Clinical physiology and functional imaging, 31(6), 445–451. doi:10.1111/j.1475-097X.2011.01040.x